The role of incretin-based therapies in the management of type 2 diabetes

Russell-Jones, D (2009) The role of incretin-based therapies in the management of type 2 diabetes Practical Diabetes International, 26 (5).

Full text not available from this repository.

Abstract

In patients with type 2 diabetes mellitus (T2DM), goals for blood glucose and other cardiovascular risk factors, such as blood pressure and body weight, can be difficult to achieve. Recent clinical trials indicate that incretin-based therapies - dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 (GLP-1) agonists - help to achieve glycaemic goals and are generally well tolerated, with a low prevalence of hypoglycaemia. GLP-1 agonists also improve weight, blood pressure and markers of β-cell function. Addition of an incretin-based agent may be appropriate for selected patients with T2DM and unsatisfactory glycaemic control on conventional therapies. Copyright © 2009 John Wiley & Sons.

Item Type:	Article
Divisions :	Surrey research (other units)
Authors :	Name Email ORCID Russell-Jones, D davidrussell-jones@nhs.net
Date :	27 November 2009
DOI :	10.1002/pdi.1368
Depositing User :	Symplectic Elements
Date Deposited :	17 May 2017 09:05
Last Modified :	24 Jan 2020 16:00
URI:	http://epubs.surrey.ac.uk/id/eprint/822233

Actions (login required)

View Item

Downloads